ORIGINAL RESEARCH article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1579411
This article is part of the Research TopicEmerging Insights into Immunological Mechanisms in Neurodegenerative, Neurogenetic, and Neurometabolic DiseasesView all 3 articles
Mirodenafil Improves Cognitive Function by Reducing Microglial Activation and Blood-Brain Barrier Permeability in ApoE4 KI Mice
Provisionally accepted- 1Department of Biomedical Science, College of Natural Sciences, Hallym University, Chuncheon-si, Republic of Korea
- 2Institute of New Frontier Research, College of Medicine, Hallym University, Chunchon, Gangwon, Republic of Korea
- 3AriBio Co. Ltd., Gyeonggi-do, Republic of Korea
- 4Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, Gangwon, Republic of Korea
- 5Hallym University, Chuncheon-si, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Alzheimer's disease (AD) has significant public health concerns in the aging society. AD can compromise brain function and lead to severe neurological abnormalities associated with dementia. The human Apolipoprotein E (ApoE4) gene is a strong risk factor for AD. However, comprehensive analyses and improvements of mouse models expressing ApoE4 remain largely unexplored.Methods: ApoE4 knock-in (KI) mice were used to investigate the role of humanized ApoE4 in hippocampal histological changes and cognitive impairment. Cerebrovascular perfusion, blood-brain barrier (BBB) integrity, microgliosis, and amyloid-beta 42 (Aβ42) accumulation were examined. Cognitive functions were assessed using the Morris water maze, Y-maze, and novel object recognition tests. Mirodenafil, a potent and selective phosphodiesterase 5 inhibitor (PDE5i), was orally administered to ApoE4 KI mice for four weeks. An in vitro BBB model and BV2 microglial cells were used to investigate endothelial permeability and inflammation.Results: ApoE4 KI mice exhibited not only reduced cerebrovascular perfusion and CLN-5 expression but also increased microgliosis and Aβ42 accumulation in the hippocampus. These phenomena were accompanied by impaired cognitive functions. Mirodenafil administration reversed the histological and behavioral alterations induced by ApoE4 KI. In vitro, mirodenafil treatment mitigated Aβ42-induced endothelial permeability and lipopolysaccharide-induced microglial inflammation.Discussion: These findings suggest that mirodenafil enhances cerebrovascular function, preserves BBB integrity, and mitigates neuroinflammation in ApoE4 KI mice, leading to cognitive improvement. PDE5 inhibition may serve as a promising therapeutic approach for addressing ApoE4-associated cerebrovascular and cognitive dysfunction.
Keywords: Alzheimer's disease, Human apolipoprotein E, cerebrovascular perfusion, Cognitive Function, Mirodenafil
Received: 21 Feb 2025; Accepted: 24 Apr 2025.
Copyright: © 2025 Park, Moon, Jung, Park, Kim, Song, In, Han, Sohn and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chan Hee Lee, Hallym University, Chuncheon-si, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.